Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 7/20 | 0.42 |
| ▸ | MAOB | P27338 | 7/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.38 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.36 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12641011 | 0.82 | BRD4 (0.44) | BRD4MAOAMAOBNPC1RAB9A | |
| SCHEMBL3452654 | 0.81 | MAOA (0.63) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL1099011 | 0.80 | FFAR1 (0.53) | BRD4MAOAMAOBFFAR1 | |
| SCHEMBL12578309 | 0.80 | BRD4 (0.42) | BRD4MAOAMAOBNPC1RAB9A | |
| SCHEMBL3630806 | 0.80 | FFAR1 (0.53) | BRD4MAOAMAOBNPC1RAB9A | |
| SCHEMBL12578308 | 0.79 | FFAR1 (0.47) | BRD4FFAR1 | |
| SCHEMBL4385708 | 0.79 | HDAC3 (0.38) | BRD4MAOAMAOBNPC1RAB9A | |
| SCHEMBL950478 | 0.79 | NPC1 (0.60) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL29955275 | 0.79 | NPC1 (0.60) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL13117479 | 0.78 | BRD4 (0.40) | BRD4MAOAMAOBFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786165-B2 | Aminophenylpropanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-31 | — | — | US | disclosed |
| US-7786165-B2 | Aminophenylpropanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-31 | — | — | US | disclosed |
| US-7786165-B2 | Aminophenylpropanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-31 | — | — | US | disclosed |
| US-7456218-B2 | 3-(4-benzyloxyphenyl) propanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-25 | — | — | US | disclosed |
| US-7456218-B2 | 3-(4-benzyloxyphenyl) propanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-25 | — | — | US | disclosed |
| US-7456218-B2 | 3-(4-benzyloxyphenyl) propanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-25 | — | — | US | disclosed |
| US-20080269220-A1 | Aminophenylpropanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080269220-A1 | Aminophenylpropanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080269220-A1 | Aminophenylpropanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20070149608-A1 | 3-(4-Benzyloxyphenyl) propanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070149608-A1 | 3-(4-Benzyloxyphenyl) propanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070149608-A1 | 3-(4-Benzyloxyphenyl) propanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
| EP-1726580-A1 | AMINOPHENYLPROPANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149608-A1 | 3-(4-Benzyloxyphenyl) propanoic acid derivatives | GPR119, GPR55, GLP1R | BRD4 1422/4885MAOA 4474/4885MAOB 4637/4885 |
| US-20080269220-A1 | Aminophenylpropanoic Acid Derivative | GPR119, GPR55, GPR65 | BRD4 2707/4885MAOA 4047/4885MAOB 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.